WEBULL
WebtradeDownload

Can Qiagen (QGEN) Look Cheap On Its New FDA Cleared Sepsis Test Push?

Simply Wall St · 1d ago

Qiagen (NYSE:QGEN) just drew fresh attention after the FDA cleared its new QIAstat Dx bloodstream infection panel, giving U.S. labs access to a full-hour-scale portfolio for rapid sepsis-related testing.

Investors have seen mixed signals around Qiagen in 2026, with the share price down 7.12% year to date but recording a 12.99% 90 day share price return and a 1.28% total shareholder return over the past year. This suggests momentum has recently picked up as the market weighs new product launches like QIAmini and the expanded QIAstat Dx portfolio against earlier weakness.

Scan how Qiagen’s sepsis-focused push compares to peers by reviewing hand-picked diagnostics and life sciences players in the 38 healthcare AI stocks that are leaning into faster, data-driven medicine.

Qiagen appears to have a solid diagnostics platform, recently cleared products and an expanding infection testing menu. The key question is whether that combination of assets is already fully reflected in today’s share price.

Most Popular Narrative: 4.5% Undervalued

Qiagen’s latest widely followed narrative pegs fair value at $46.27, a little above the last close at $44.18. This keeps attention firmly on whether automation, sepsis testing and TB assays can support that gap over time.

The main requirement is that Qiagen sustains QuantiFERON growth in non immigration testing while scaling higher margin digital PCR and bioinformatics, so that the business benefits from current investments in automation, AI and portfolio reshaping.

See why 11 investors see Qiagen as 5% undervalued.

Result: Fair Value of $46.27 (UNDERVALUED)

Still, Qiagen’s story could be knocked off course if research funding stays tight and QuantiFERON immigration testing remains weak for longer than analysts expect.

Find out about the key risks to this Qiagen narrative.

Next Steps

Mixed signals or a setup worth watching: act before the next narrative forms around Qiagen and run the numbers yourself using the 2 key rewards and 1 important warning sign.

Looking for more Qiagen investment ideas?

Before moving on, put Qiagen’s story in context by lining it up against other opportunities that could sharpen your watchlist and broaden your next moves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.